MedTrace Logo

Performance of Systane PRO Versus Refresh Optive Mega-3

NCT06975891 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-04-13

No results posted yet for this study

Summary

Single site, prospective, double-masked, randomized-controlled, cross-over study of the subjective and objective performance of 2 different eyedrops. Subjects will be assessed at a screening visit, and 3 follow-up visits. Clinical evaluations will include patient questionnaires.

Conditions

  • Dry Eye

Interventions

DRUG

Systane PRO

Lubricating Eyedrops

DRUG

Refresh Optive MEGA-3

Lubricating Eyedrops

Sponsors & Collaborators

  • Sengi

    collaborator INDUSTRY

  • Scripps Poway Eyecare and Optometry

    lead OTHER

Principal Investigators

  • Jay Mashouf, OD · Scripps Optometric Group

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-15
Primary Completion
2025-09-30
Completion
2025-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06975891 on ClinicalTrials.gov